证券代码：301156 证券简称：美农生物 公告编号：2025-037 上海美农生物科技股份有限公司 关于部分董事、高级管理人员股份减持计划的预披露公告 公司董事、高级管理人员熊英保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 1、截至本公告披露日，上海美农生物科技股份有限公司（以下简称"公司"） 总股本为 140,784,675 股。 2、持有公司股份 4,981,049 股（占公司总股本比例 3.54%）的董事、高级管 理人员熊英，计划自本公告披露之日起 15 个交易日后的 3 个月内以集中竞价、 大宗交易的方式减持其持有的公司股份不超过 1,245,262 股（占公司总股本比例 0.88%）。 二、本次减持计划的主要内容 1、减持目的：个人资金需求。 2、股份来源：公司首次公开发行前持有及上市后权益分派取得的股份。 近日，公司收到公司董事、高级管理人员熊英出具的《关于减持所持上海美 农生物科技股份有限公司股份的减持计划告知函》，现将具体事项公告如下： 一、股东的基本情况 截至本公告日，拟 ...

Core Insights - The company reported a year-on-year decline in net profit primarily due to intensified domestic market competition, decreased investment income, and reduced subsidy income [1] - Despite the domestic business downturn, the company's international operations showed robust growth, with overseas revenue increasing by 25% year-on-year [1] - The company plans to enhance its investment in international markets in 2025 to maintain its competitive edge and drive continued growth [1] Company Overview - The company, established in 1997, specializes in the research, production, and sales of feed additives, with over 27 years of industry experience [2] - Its products are widely used in various animal sectors, including pigs, ruminants, poultry, and aquaculture, playing a crucial role in improving feed intake, digestion, gut health, growth promotion, milk quality, and feed resource efficiency [2] Future Plans - The company is advancing a corn protein processing project with an annual capacity of 100,000 tons, expected to be completed in 2025, which will optimize product structure and create new revenue growth points [1]

Group 1: Company Strategy and Product Development - The company adopts a "segmented species, comprehensive nutrition" product development strategy, establishing a diverse product system to enhance competitive advantages in a challenging market [2][3] - Various comprehensive solutions are provided to meet different customer needs, such as improving animal feed intake and maintaining gut health [3] - The company focuses on continuous product innovation and development, particularly in the fields of feed additives and enzymatic protein feed materials [4][7] Group 2: Market Position and Growth Opportunities - The company has a global market presence, covering various animal categories including pigs, poultry, ruminants, and aquaculture [4] - International market revenue increased by 25% year-on-year, while domestic market revenue has faced challenges for three consecutive years [6][9] - The company plans to expand its product applications in ruminants and aquaculture to mitigate risks associated with the cyclical nature of the pig farming industry [5][9] Group 3: Financial Performance and Management - In Q1 2025, the company reported revenue of 99.85 million, a year-on-year increase of 1.99%, while net profit decreased by 5.4% [6][9] - The company emphasizes cash flow management through inventory optimization and accounts receivable recovery, aiming to enhance operational cash flow [5][9] - R&D investment decreased by 4.93%, but the number of R&D personnel increased by 7.25%, indicating a focus on maintaining technological advantages [8][10] Group 4: Future Outlook and Risk Management - The company acknowledges uncertainties in the market, such as competition and raw material price fluctuations, but views these as both challenges and opportunities [4][9] - The company is committed to enhancing its operational quality and creating sustainable returns for investors through improved communication and engagement [6][9] - The company is advancing a corn protein processing project with an annual capacity of 100,000 tons, expected to be operational by 2025, to optimize product structure and create new revenue streams [9][10]

2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 证券代码：301156 证券简称：美农生物 公告编号：2025-036 上海美农生物科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形； 1、现场会议召开时间：2025 年 5 月 16 日（星期五）14:30； 2、网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进 行网络投票的具体时间为：2025 年 5 月 16 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深交所互联网投票系统投票的具体时间为：2025 年 5 月 16 日 9:15-15:00。 （二）召开地点：上海市嘉定区沥红路 151 号公司会议室 （三）召开方式：采取现场投票与网络投票相结合的方式 （四）召集人：上海美农生物科技股份有限公司（以下简称"公司"）董事会 （五）会议主持人：董事长洪伟先生 （六）本次股东大会的召集、召开及表决程序符合《中华人 ...

北京市天元律师事务所 关于上海美农生物科技股份有限公司 致：上海美农生物科技股份有限公司 上海美农生物科技股份有限公司（以下简称"公司"）2024 年年度股东大会（以 下简称"本次股东大会"）采用现场投票与网络投票相结合的方式召开，现场会议于 2025 年 5 月 16 日 14:30 在上海市嘉定区沥红路 151 号公司会议室召开。北京市天 元律师事务所（以下简称"本所"）接受公司聘任，指派本所律师参加本次股东大会 现场会议，并根据《中华人民共和国公司法》、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）以 及《上海美农生物科技股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，就本次股东大会的召集、召开程序、出席会议人员的资格、召集人资格、会议 表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《上海美农生物科技股份有限公司第五届 董事会第十一次会议决议公告》《上海美农生物科技股份有限公司第五届监事会第 十次会议决议公告》《上海美农生物科技股份有限公司关于召开 2024 年年度股东 大会的通知》（以下简称"《召开 ...

Market Overview - A-shares experienced a downward trend, with the Shanghai Composite Index closing at 3380.82, down 0.68%, and the Shenzhen Component Index down 1.62% at 10186.45 [1] - The Hong Kong market also declined, with the Hang Seng Index falling nearly 1% and the Hang Seng Tech Index down 1.5% [1] Consumer Sector Performance - The consumer sector showed strong performance, particularly in beauty and personal care, which rose by 6.46%, with 31 out of 33 stocks increasing [2] - The cosmetics segment led the A-share market with no stocks declining, and significant gains were noted for companies like Bawei Co. and Qingsong Co. [2] - Retail sales in the cosmetics sector are projected to reach 114.9 billion yuan by Q1 2025, reflecting a 3.20% year-on-year growth [2] Promotional Activities and Market Dynamics - Major platforms like Tmall, Douyin, and JD.com are intensifying competition with synchronized promotional events starting on May 13 [3] - The beauty and personal care sector is expected to see structural opportunities due to extended promotional periods and product innovation [3] - The apparel sector also showed activity, with companies like Anzheng Fashion hitting the daily limit [3] Synthetic Biology Sector - The synthetic biology concept saw a rise, particularly after a promotional campaign by Kelun Pharmaceutical, which boosted interest in the sector [4] - The synthetic biology sector's overall increase was 2.05%, with several stocks achieving significant gains [4] - The demand for bio-based materials and pharmaceutical intermediates is expected to grow, providing a broad market for synthetic biology companies [5] Shipping and Port Sector - The shipping sector saw a resurgence, with the European shipping index rising by 8.72% [7] - Companies like China National Offshore Oil Corporation and Ningbo Port experienced significant stock price increases, with some stocks hitting the daily limit [7] - Recent adjustments in U.S.-China tariff policies have led to a surge in exports to the U.S., boosting shipping volumes [7][8]

Group 1 - The pet economy concept rose by 1.98%, ranking third among concept sectors, with 54 stocks increasing in value, including major gainers like Meino Biological and Jieya Co., which hit the 20% limit up [1][2] - Notable stocks with significant increases include Xianle Health, Huisheng Biological, and Yiyuan Magic Yam, which rose by 13.41%, 10.50%, and 9.10% respectively [1] - The leading decliners in the sector were Zhiou Technology, Qingmu Technology, and Yingstone Network, which fell by 4.64%, 4.42%, and 2.73% respectively [1] Group 2 - The pet economy sector saw a net inflow of 236 million yuan, with 48 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top stock for net inflow was Yong'an Pharmaceutical, with a net inflow of 68.36 million yuan, followed by Jieya Co., Ruoyuchen, and Meino Biological with net inflows of 48.24 million yuan, 46.14 million yuan, and 45.47 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Jieya Co., Jiabiyou, and Meino Biological led with net inflow rates of 27.98%, 13.31%, and 11.04% respectively [3] - The pet economy sector's inflow ranking included stocks like Yong'an Pharmaceutical, Jieya Co., Ruoyuchen, and Meino Biological, all showing strong performance in terms of trading volume and turnover rates [3][4]

Group 1 - The vitamin concept sector rose by 1.55%, ranking 6th among concept sectors, with 48 stocks increasing in value, including Meino Biological reaching a 20% limit up [1][2] - Notable gainers in the vitamin sector included Xiwang Food, Yong'an Pharmaceutical, and Jindawei, which all hit the limit up, while Xianle Health, Oukang Pharmaceutical, and Fujilai also saw significant increases of 13.41%, 8.31%, and 6.54% respectively [1][2] - The sector experienced a net inflow of 548 million yuan from main funds, with 41 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow, led by Jindawei with 155 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jindawei, Xiwang Food, and Andisu, with net inflow ratios of 29.36%, 27.57%, and 20.19% respectively [3][4] - The trading volume and turnover rates for leading stocks in the vitamin sector were significant, with Jindawei showing a turnover rate of 4.82% and a price increase of 9.99% [3][4] - Other notable stocks included Yong'an Pharmaceutical with a 9.99% increase and a turnover rate of 31.54%, and Zhejiang Pharmaceutical with a modest increase of 0.29% [3][4]

Market Overview - The market experienced a volume contraction with the ChiNext index dropping nearly 2% by the end of the day. The synthetic biology concept stocks surged, with companies like Chuaning Biological, Jieya Co., and Meinong Biological hitting the daily limit. The shipping sector saw a rise and subsequent fall, with Ningbo Shipping, Ningbo Ocean, and Lianyungang achieving three consecutive limits. Consumer stocks in food, apparel, and beauty care were active, with Xiwang Food, Lafang Cosmetics, and Fengzhu Textile also hitting the daily limit. Conversely, the military industry faced adjustments, with Tianjian Technology nearing a limit down, and computing power concept stocks weakened, with Hongjing Technology dropping nearly 10%. Overall, over 3,800 stocks in the Shanghai and Shenzhen markets declined, with a total transaction volume of 1.19 trillion [1]. Hot Topics Health Products - Kolun Pharmaceutical's advertisement for ergothioneine capsules has sparked significant discussion, with Chairman Liu Gexin personally endorsing the product. Ergothioneine is a natural small molecule derived from histidine thiourea, found in microbial cells and plants. It cannot be synthesized by the human body and must be obtained through diet, with mushrooms being a key source. Sales of oral beauty products containing ergothioneine on a major e-commerce platform surged by 60 times year-on-year in the first half of 2024 [4][5]. Shipping - The shipping sector remained active, with Ningbo Ocean and Lianyungang achieving three consecutive limits. Following trade negotiations between China and the U.S., container shipping bookings from China to the U.S. surged nearly 300%, with the average booking volume for 20-foot standard containers skyrocketing to 21,530, up from 5,709 a week prior. Goldman Sachs anticipates a significant increase in Chinese exports over the next 90 days due to a tariff suspension [6][8]. Consumer Sector - The consumer sector was lively, with stocks like Marubi, Dengkang Dental, and Baiyang hitting the daily limit. The Tmall 618 promotion commenced, with the first hour's GMV for popular beauty products increasing over 10% year-on-year. Additionally, the price of tilapia has risen to 4.5 yuan per pound, with China being a major producer and exporter of tilapia, producing over 1.6 million tons annually, with about a quarter exported to the U.S. [9][10]. Stock Performance - Notable stocks in the health products sector include: - Jiaoda Aongli (600530.SS) with a price of 7.50, up 9.97%, and a market cap of 5.812 billion - Lafang Cosmetics with a price of 21.97, up 10.02%, and a market cap of 4.948 billion - Chuaning Biological with a price of 14.02, up 20.03%, and a market cap of 8.635 billion [5][10]. - In the shipping sector: - Ningbo Ocean (601022.SS) at 11.12, up 9.99%, with a market cap of 2.765 billion - Lianyungang (601008.SS) at 6.77, up 10.08%, with a market cap of 8.399 billion [7][10]. - In the consumer sector: - Zhejiang Yongqiang (002489.SZ) at 4.07, up 10.00%, with a market cap of 7.786 billion - Marubi (603983.SS) at 52.53, up 10.01%, with a market cap of 21.065 billion [10].

Group 1: International Market Development - The company has established a sales network in over 40 countries and regions, including Vietnam, Russia, Thailand, and Brazil, by the end of 2024 [3][10] - International market business revenue grew by over 25% year-on-year in 2024, with overseas business accounting for over 38% of total revenue [3][9] - The company aims to enhance its international market influence and position through increased investment and product launches along the "Belt and Road" initiative [3][9] Group 2: Competitive Advantages - The company has over 20 years of experience in international market development, establishing a unique brand image and a comprehensive sales network [4] - A high-quality, professional international team provides comprehensive services to overseas distributors and customers, enhancing brand value and differentiation [4] - The company actively participates in global exhibitions and forums to strengthen its brand presence in international markets [4] Group 3: Corn Protein Processing Project - The company is investing in a corn protein processing project with an annual capacity of 100,000 tons, addressing the domestic shortage of feed protein resources [5][6] - The project is expected to enhance the nutritional value and functionality of corn protein products, aligning with national industry policies [5][6] - Upon full completion, the project will provide a diverse product range, mitigating market volatility risks and expanding revenue growth opportunities [6][7] Group 4: Product Strategy and Market Focus - The company’s product strategy emphasizes "diversified nutrition" and focuses on pigs, ruminants, poultry, and aquaculture [12] - In 2024, the revenue breakdown for main products was 60.93% for functional feed additives, 19.97% for nutritional feed additives, and 12.84% for enzymatic protein feed materials, with growth rates of 6.77% and 9.81% respectively [11] - The company plans to enhance its product line and market presence through increased R&D investment and the introduction of high-value products [12]